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To the editor: 
 
We read the editorial “The time is right for an international primary ciliary dyskinesia disease registry” with 
interest [1]. Haver discusses our recent article on the international primary ciliary dyskinesia cohort (iPCD 
Cohort) [2] and stresses three aims important to primary ciliary dyskinesia research: the development of a 
prospective international PCD registry, the standardisation of data collection, and the achievement of an 
international diagnostic consensus. We support these aims and here highlight ongoing activities that 
support them.  
 
Patient registries collecting relevant epidemiological data are key instruments for research on rare 
diseases that improve patient care and healthcare planning [3]. To answer the need for collaborative 
research in PCD, the European Union's Seventh Framework Programme (EU FP7) project BESTCILIA 
and the BEAT-PCD Cost Action have taken several initiatives.  
 
BESTCILIA allowed setting up both the retrospective iPCD cohort [2] and a prospective international PCD 
registry [4]. The iPCD Cohort [2] is the first effort to combine all available datasets on PCD patients 
collected by published research studies, local case series, and national registries. It thus includes patients 
diagnosed back to the 1960s. Due to the retrospective nature of the iPCD cohort and the evolution of 
diagnostics since the 1960s, it was not possible, as Haver notes, to achieve complete consensus on the 
diagnostic data and clinical information for all patients. However, extensive discussions among all 
researchers produced agreement on the most relevant variables. 
 
The international PCD registry [4] was developed in collaboration between European and North American 
researchers and PCD support groups. It collects prospective PCD patient data and also unites existing 
national PCD registries. The registry items, developed as a consensus result of the BESTCILIA 
consortium, collect diagnostic information in a standardised format. Despite this the registry does not 
contain information on all available diagnostic tests (nasal NO, high-speed video microscopy, 
transmission electron microscopy, genetics, immunofluorescence, and others) for each patient because 
not every contributing centre can use every diagnostic method. Also, the number of tests needed to make 
a diagnosis varies depending on patient phenotype. 
 
Clinical information reported in medical research is indeed still far from standardised and clinical 
assessment and descriptions of symptoms of PCD patients vary widely [5]. For this reason, a 
multidisciplinary group of experts working in the framework of the COST Action BEAT-PCD[6] is further 
standardising data collection with two ongoing projects: the development of disease-specific standardised 
proformas for assessment of clinical data in PCD routine care, and a prospective observational study 
(PROVALF) evaluating intra-individual variation of lung function parameters in stable PCD patients. Both 
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projects aim to improve availability of standardised longitudinal data of PCD patients for use in clinical 
care and research.  
 
Regarding the need for diagnostic consensus as a base for a PCD registry, this is a crucial step. 
However, the process is complicated by the heterogeneous nature of PCD and limited evidence on the 
validity of existing diagnostic techniques. The recent ERS Task Force guidelines for the diagnosis of PCD 
[7] summarised the level of consensus it was possible to reach regarding the use of diagnostic tests to 
confirm or exclude PCD. Although this is an important step, we still deal with diagnostic challenges such 
as variation in the availability of tests between countries and the lack of standardisation of some tests. 
This is a reality even in countries with well-developed health services. In the USA, high-speed video 
microscopy is rarely used, while in Europe the clinical availability of genetic testing is limited. 
   
In the iPCD cohort, we applied the definitions set by the ERS Task Force to classify patients. Clinical 
features continue to play an important role in the diagnosis of PCD given existing tests [7]. The 
BESTCILIA consortium thus decided to include all patients followed up as PCD by the participating 
centres and then stratify data analyses according to diagnostic certainty. To further improve diagnostic 
information in the iPCD cohort, we encourage participating centres to repeat diagnostic testing in older 
patients using state-of-the-art techniques and to update diagnostic data in the iPCD datasets.  
 
Achieving diagnostic consensus and collecting prospective data from many patients are jointly necessary, 
but both can take time. We therefore stress the importance of using all available data for research in rare 
diseases such as PCD so as not to let the perfection of datasets retard research advances that can help 
patients. Information already included in datasets such as the iPCD cohort can offer valuable insight into 
the disease and inform the development of prospective studies to come.     
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